Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis

SIMPLE SUMMARY: The standard treatment for Hodgkin lymphoma (HL) patients presenting a relapsed/refractory (R/R) disease is salvage chemotherapy followed by autologous stem cell transplantation (ASCT). With commonly used chemotherapy combinations, 25–30% fail to proceed to ASCT, with poor outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Massaro, Fulvio, Meuleman, Nathalie, Bron, Dominique, Vercruyssen, Marie, Maerevoet, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869808/
https://www.ncbi.nlm.nih.gov/pubmed/35205729
http://dx.doi.org/10.3390/cancers14040982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869808/
https://www.ncbi.nlm.nih.gov/pubmed/35205729
http://dx.doi.org/10.3390/cancers14040982

Ejemplares similares